{"entity":{"id":"immune-cytotoxicity-assays","kind":"term","name":"Immune-cell cytotoxicity assays","aka":["immune cytotoxicity assay","target-cell killing assay"],"tldr":"These experiments measure whether immune cells cause death of specified target cells. The target cells, comparison conditions and timing are part of the result.","summary":"A primary flow-cytometry method distinguished labeled target cells from immune effector cells and measured target death while characterizing the effector population. The study examined how timing and the effector-to-target ratio affected the assay. Degranulation markers provide a related functional readout, but they measure a step preceding cytolysis. Killing of a laboratory target does not establish recognition of every tumor cell or benefit in the person receiving a treatment.","asOf":"2026-11-10","links":[{"label":"A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.","url":"https://doi.org/10.1016/j.jim.2007.05.013"},{"label":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.","url":"https://doi.org/10.1016/s0022-1759(03)00265-5"},{"label":"A versatile flow-based assay for immunocyte-mediated cytotoxicity.","url":"https://doi.org/10.1016/j.jim.2019.112668"},{"label":"Cell-based flow cytometry assay to measure cytotoxic activity.","url":"https://doi.org/10.3791/51105"}],"tags":[],"related":["elispot","peptide-hla-multimer-staining","cell-therapy-release-testing"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Method card, what it measures: whether specified effector cells cause death of specified target cells under controlled laboratory conditions, at a stated effector-to-target ratio and time. Readouts: flow cytometry that separates labelled targets from effectors and uses death-associated staining, release assays, or imaging over time. A fall in a metabolic or growth signal can reflect slowed growth and not death, so it needs validation as evidence of killing. Controls: target-only survival wells, effector identification and viability, a positive-control response, irrelevant or antigen-negative targets and suitable antigen or presentation perturbations, plus maximum release where relevant. Failure modes: high spontaneous death, mistaken target identity, aggregates, dye transfer, artificial loading, mismatched ratios or a readout that mainly measures growth.","Background arithmetic, fictional: matched wells of 100 identifiable targets show 30% death without effectors and 40% with them at the same 2-hour endpoint. Raw death is 40%, but 30% occurs without effectors, so the excess is 40 minus 30 = 10 percentage points. That excess is associated with the tested condition and does not identify which deaths the effectors caused, and calling the result 40% immune killing is not justified. A control-normalised specific-lysis formula gives a different quantity from an excess-death calculation, so the method has to be named, and a high baseline death can make the experiment unsuitable.","Scope of the methods: a flow-based assay labels targets with a dye, adds a dead-cell stain and analyses released nuclei, which lowers errors from target-effector aggregates, and it reported four nuclear staining patterns separating target and effector nuclei and live and dead cells (Rabinovich 2019). A peptide-pulsed target assay compares CFSE-low peptide-loaded and CFSE-high unloaded CD4 T-cell targets and calculates lytic units from specific lysis at several ratios (Noto 2013), so its result belongs to that artificial peptide loading, which can bypass the tumour's own processing. Degranulation (CD107 exposure) preceded cytolysis and was concordant with interferon gamma in the original report, and is distinct from completed target death (Betts 2003). Model-specific killing does not show trafficking, persistence, healthy-tissue safety or patient benefit.","Keep the identities and preparation of both effector and target cells, whether a cell line, engineered target or patient-derived preparation, together with medium, effector-to-target ratio and exposure time. Culture can change the tested population. The output might be a fraction of identified targets dead, a viable target count, release under a specified normalisation, or a time curve; these are different quantities. A negative is interpretable only when cell health, target suitability and controls support the experiment, and no universal laboratory killing cut-off establishes clinical efficacy. Reproducibility and biological specificity need checking for the specimen, model and intended claim."],"category":"Immunology"},"route":"/terms/immune-cytotoxicity-assays/","neighbours":{"term":[{"id":"elispot","kind":"term","name":"ELISpot secretion assays","route":"/terms/elispot/"},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immunogenicity-versus-efficacy","kind":"term","name":"Immunogenicity and clinical efficacy","route":"/terms/immunogenicity-versus-efficacy/"},{"id":"intracellular-cytokine-staining","kind":"term","name":"Intracellular cytokine staining","route":"/terms/intracellular-cytokine-staining/"},{"id":"binding-presentation-recognition","kind":"term","name":"Peptide binding, presentation and immune recognition","route":"/terms/binding-presentation-recognition/"},{"id":"peptide-hla-multimer-staining","kind":"term","name":"Peptide-HLA multimer staining","route":"/terms/peptide-hla-multimer-staining/"},{"id":"tcr-repertoire-clonality","kind":"term","name":"T-cell receptor repertoire diversity and clonality","route":"/terms/tcr-repertoire-clonality/"}],"technology":[{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/"}]}}